RiverVest News

By:  Brian Feldt, Reporter
St. Louis Business Journal

December 26, 2014

 

RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology.

This year may be its best campaign yet.

RiverVest exited a dozen portfolio companies since 2011, returning $290.5 million to the firm, or 3.5 times the dollars invested in those companies ($83 million).  Read more.

Source: St. Louis Business Journal

By:  Brian Feldt, St. Louis Business Journal

September 8, 2014

Tryton Medical, a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors that includes St. Louis-based RiverVest Venture Partners and the 3×5 Special Opportunity Fund.

Both RiverVest and the 3X5 fund, which is co-managed by RiverVest, have participated in funding rounds for Tryton before, most recently in a $24 million equity financing round for the Durham, North Carolina-based company in early 2013.   Read more

ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.

By Josh Baxt, BioSpace.com Exclusive Story

July 21, 2014

In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets.

For cash-strapped startups, this represents an opportunity, but they need to understand the rules. RiverVest is trying to build companies in five years or less, and that means having excellent IP and a collaborative team to take it towards the finish line.  Read More

 

Medical Device and Diagnostic Industry
May 28, 2014
Jamie Hartford

 No. 7: RiverVest Venture Partners

Passion or the desire to make a difference alone cannot bring about radical changes in the world of medtech. Money and the right guidance are equally crucial. That’s where venture capitalist firms—especially RiverVest Venture Partners—come in.  Read More

ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner.

St. Louis Business Journal
March 7, 2014
Brian Feldt, Reporter

Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round.

ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday.

ST. LOUIS and WASHINGTON, D.C. (Nov. 5, 2013) –RiverVest Venture Partners’ Bradley T. Keller presents research today on a potential new treatment for cholestatic liver diseases at The Liver Meeting in Washington, D.C. 

ST. LOUIS, MO (July 15, 2013) – RiverVest Venture Partners announced today that Abbott Laboratories is acquiring RiverVest medical device portfolio company IDEV Technologies for $310 million.